Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy

• DOI: 10.1371/journal.pone.0229754
• Publication Date: 2020-03-05T18:41:41Z
• Authors: Zongwei Wang; Tuo Deng; Xingbo Long; Xueming Lin; Shulin Wu; Hongbo Wang; Rongbin Ge; Zhenwei Zhang; Chin-Lee Wu; Mary-Ellen Taplin; Aria F. Olumi
• Keywords: CpG site

To determine whether SRD5A2 promoter methylation is associated with cancer progression during androgen deprivation therapy (ADT) in CRPC.